Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers [PDF]
, 2021 Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Onno A. Spruijt +31 more
core +1 more source
Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties [PDF]
, 2011 Reduced NO levels due to the deficiency of tetrahydrobiopterin (BH4) contribute to impaired vasodilation in pulmonary hypertension Due to the chemically unstable nature of BH4 it was hypothesised that oxidatively stable analogues of BR, would be able to ...
Roger M. Wadsworth +9 more
core +4 more sources
Repurposing of medications for pulmonary arterial hypertension [PDF]
, 2020 This manuscript on drug repurposing incorporates the broad experience of members of the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory ...
Spiekerkoetter, Edda +11 more
core +4 more sources
Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension [PDF]
, 2011 Background: Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Norbert Weissmann +41 more
core +2 more sources
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. [PDF]
, 2005 BACKGROUND: Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur.
Shakur, B Haleema +17 more
core +2 more sources
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. [PDF]
, 2003 BACKGROUND\ud \ud Mutations of the transforming growth factor beta (TGFbeta) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT).
Flanagan, J A +16 more
core +1 more source
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood [PDF]
, 2005 BACKGROUND: Pulmonary arterial hypertension (PAH) is a potentially fatal vasculopathy that can develop at any age. Adult-onset disease has previously been associated with mutations in BMPR2 and ALK-1.
Haworth, SG +22 more
core +1 more source
Non-Invasive Pulmonary Artery Wave Intensity Analysis in Pulmonary Hypertension. [PDF]
, 2015 Pulmonary wave reflections are a potential hemodynamic biomarker for pulmonary hypertension (PH) and can be analyzed using wave intensity analysis (WIA). In this study we used pulmonary vessel area and flow obtained using cardiac magnetic resonance (CMR)
Moledina, S +17 more
core +1 more source
Neurohormonal modulation in pulmonary arterial hypertension
, 2021 Pulmonary hypertension is a fatal condition of elevated pulmonary pressures, complicated by right heart failure. Pulmonary hypertension appears in various forms; one of those is pulmonary arterial hypertension (PAH) and is particularly characterized by ...
de Man, Frances S. +3 more
core +1 more source
Distinct Platelet Ribonucleic Acid Signatures in Patients with Pulmonary Hypertension
, 2022 Rationale: Pulmonary hypertension encompasses progressive disorders leading to right ventricular dysfunction and early death. Late detection is an important cause of poor clinical outcomes.
Smits, A Josien +19 more
core +1 more source